Γ
Content Highlights || Full Agenda
Spotlight Talk

2:10 PM

-

2:15 PM

AIxBIO

From Cells to Simulation: Building the Data Engine for Predictive Human Biology

The primary barrier to a general-purpose biological simulator, (a model that can actually predict the phenotypic level response of the human body to any intervention),  is not a lack of compute, but the absence of causal, human-relevant datasets. In this talk, Matt Osman outlines emerging approaches to address this gap through iPSC-derived tissues that function as both therapeutic platforms and scalable engines for data generation. Polyphron explores why high-fidelity human tissue is uniquely capable of capturing emergence, where molecular interactions translate into functional outcomes, and why generating this data across diverse genotypes is essential to building true ground-truth datasets. By closing the loop between lab-grown tissue and clinical outcomes, this approach points toward a shift from sparse, mechanism-limited data to a more predictive and programmable framework for human health.

Spotlight Talk

2:10 PM

-

2:15 PM

AIxBIO

From Cells to Simulation: Building the Data Engine for Predictive Human Biology

The primary barrier to a general-purpose biological simulator, (a model that can actually predict the phenotypic level response of the human body to any intervention),  is not a lack of compute, but the absence of causal, human-relevant datasets. In this talk, Matt Osman outlines emerging approaches to address this gap through iPSC-derived tissues that function as both therapeutic platforms and scalable engines for data generation. Polyphron explores why high-fidelity human tissue is uniquely capable of capturing emergence, where molecular interactions translate into functional outcomes, and why generating this data across diverse genotypes is essential to building true ground-truth datasets. By closing the loop between lab-grown tissue and clinical outcomes, this approach points toward a shift from sparse, mechanism-limited data to a more predictive and programmable framework for human health.

SynBioBeta is where the people building with biology meet the people funding, buying, and partnering with them. If you're raising capital, scouting the next wave of AIxBIO companies, or looking for your next technology partner - the people you need are here for three days.

The startups on stage this year are building programmable RNA medicines, virtual cell models, AI-designed enzymes, and proteins that replace sugar - alongside GSK, Sanofi, Novo Nordisk, Eli Lilly, J&J, Mars, Apple, Google, NVIDIA, Unilever, and P&G.

Watching where the partnerships form and which technologies the biggest players are actually evaluating is something you can't get from a report or a webinar. And our 1:1 Partnering App lets you book meetings before you arrive.

“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”

Eric Schmidt

Former CEO

"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."

Celestine Schnugg

Founder

"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."

Surge Biswas

Founder

"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."

Jacob Glanville

Founder & CEO

"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."

Bill Tai

Co-founder

"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."

Luis Cascao-Pereira

Head of Digital Biology

"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."

Ola Wlodek

CEO

Who’s Coming to SynBioBeta?

And the BD and R&D Leads
That Will Be Your Customers and Partners: